Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 31997R1837

    Commission Regulation (EC) No 1837/97 of 24 September 1997 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)

    OJ L 263, 25.9.1997, p. 9–13 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

    This document has been published in a special edition(s) (CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO)

    Legal status of the document No longer in force, Date of end of validity: 05/07/2009; Implicitly repealed by 32009R0470

    ELI: http://data.europa.eu/eli/reg/1997/1837/oj

    25.9.1997   

    EN

    Official Journal of the European Communities

    L 263/9


    COMMISSION REGULATION (EC) No 1837/97

    of 24 September 1997

    amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin

    (Text with EEA relevance)

    THE COMMISSION OF THE EUROPEAN COMMUNITIES,

    Having regard to the Treaty establishing the European Community,

    Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 749/97 (2), and in particular Articles 6, 7 and 8 thereof,

    Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;

    Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;

    Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);

    Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney; whereas, however, the liver and kidney are frequently removed from carcasses moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;

    Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;

    Whereas, febentel, fenbendazole, oxfendazole and dexamethasone should be inserted into Annex I to Regulation (EEC) No 2377/90;

    Whereas bromide, sodium salt should be inserted into Annex II to Regulation (EEC) No 2377/90;

    Whereas, in order to allow for the completion of scientific studies, ceftiofur, danofloxacin and netobimin should be inserted into Annex III to Regulation (EEC) No 2377/90;

    Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorizations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851/EEC (3), as last amended by Directive 93/40/EEC (4), to take account of the provisions of this Regulation;

    Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

    HAS ADOPTED THIS REGULATION:

    Article 1

    Annexes I, II and III to Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.

    Article 2

    This Regulation shall enter into force on the 60th day following its publication in the Official Journal of the European Communities.

    This Regulation shall be binding in its entirety and directly applicable in all Member States.

    Done at Brussels, 24 September 1997.

    For the Commission

    Martin BANGEMANN

    Member of the Commission


    (1)  OJ L 224, 18. 8. 1990, p. 1.

    (2)  OJ L 110, 26. 4. 1997, p. 24.

    (3)  OJ L 317, 6. 11. 1981, p. 1.

    (4)  OJ L 214, 24. 8. 1993, p. 31.


    ANNEX

    The Annexes to Regulation (EEC) No 2377/90 are hereby amended as follows:

    A.

    Annex I is amended as follows:

    2.

    Antiparasitic agents

    2.1.

    Agents acting against endoparasites

    2.1.3.

    Benzimidazoles and pro-benzoimidazoles

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘2.1.3.1.

    Febantel

    Sum of extractable residues which may be oxidized to oxfendazole sulphone

    Bovine, ovine, porcine, equidae

    50 μg/kg

    Muscle

     

    50 μg/kg

    Fat

    500 μg/kg

    Liver

    50 μg/kg

    Kidney

    Bovine, ovine

    10 μg/kg

    Milk

    2.1.3.2.

    Fenbendazole

    Sum of extractable residues which may be oxidized to oxfendazole sulphone

    Bovine, ovine, porcine, equidae

    50 μg/kg

    Muscle

     

    50 μg/kg

    Fat

    500 μg/kg

    Liver

    50 μg/kg

    Kidney

    Bovine, ovine

    10 μg/kg

    Milk

    2.1.3.3.

    Oxfendazole

    Sum of extractable residues which may be oxidized to oxfendazole sulphone

    Bovine, ovine, porcine, equidae

    50 μg/kg

    Muscle

     

    50 μg/kg

    Fat

    500 μg/kg

    Liver

    50 μg/kg

    Kidney

    Bovine, ovine

    10 μg/kg

    Milk’

    5.

    Corticoids

    5.1.

    Glucocorticoids

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘5.1.1.

    Dexamethasone

    Dexamethasone

    Bovine, porcine, equidae

    0,75 μg/kg

    Muscle

     

    2,0 μg/kg

    Liver

    0,75 μg/kg

    Kidney

    Bovine

    0,3 μg/kg

    Milk’

    B.

    Annex II is amended as follows:

    1.

    Inorganic compounds

    Pharmacologically active substance(s)

    Animal species

    Other provisions

    ‘1.29.

    Bromide, sodium salt

    All food producing mammals

    For topical use only’

    C.

    Annex III is amended as follows:

    1.

    Anti-infectious agents

    1.2.

    Antibiotics

    1.2.4.

    Cephalosporins

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘1.2.4.1.

    Ceftiofur

    Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur

    Bovine

    2 000 μg/kg

    Liver, kidney

    200 μg/kg

    Muscle

    600 μg/kg

    Fat

    100 μg/kg

    Milk

    Provisional MRLs expire on 1. 1. 1999’

    Porcine

    4 000 μg/kg

    Kidney

    3 000 μg/kg

    Liver

    500 μg/kg

    Muscle

    600 μg/kg

    Fat

    1.2.6.

    Quinolones

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘1.2.6.1.

    Danofloxacin

    Danofloxacin

    Bovine

    900 μg/kg

    Liver

    500 μg/kg

    Kidney

    300 μg/kg

    Muscle

    200 μg/kg

    Fat

    Provisional MRLs expire on 1. 1. 1999’

    Chicken

    1 200 μg/kg

    Liver, kidney

    600 μg/kg

    Skin + fat

    300 μg/kg

    Muscle

    2.

    Antiparasitic agents

    2.1.

    Agents acting against endo-parasites

    2.1.1.

    Benzimidazoles and pro-benzoimidazoles

    Pharmacologically active substance

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    ‘2.1.1.9.

    Netobimin

    Sum of netobimin and albendazole and metabolites of albendazole measured as 2-amino-benzimidazole sulphone

    Bovine, ovine, caprine

    100 μg/kg

    Muscle, fat

    Provisional MRLs expire on 31. 7. 1999’

    1 000 μg/kg

    Liver

    500 μg/kg

    Kidney

    100 μg/kg

    Milk


    Top